The Monsanto-Bayer Merger: Anatomy of a $63 Billion Deal
The acquisition of Monsanto by Bayer closed in June 2018, creating an agricultural conglomerate with combined annual revenue exceeding $26 billion. The deal reshaped the global seed and crop-chemical landscape, giving Bayer control of Monsanto's extensive trait library, including dominant corn and soybean genetics, and the world's best-selling herbicide, Roundup. Regulatory approval came after Bayer divested parts of its own business to BASF to satisfy competition concerns in several markets.
More from this site
Keep reading the latest coverage
Bayer's stated goal was to build a platform company for crop innovation, integrating Monsanto's digital farming tools and breeding pipelines with Bayer's pharmaceutical and consumer health divisions. For farmers, the merger meant one fewer major competitor in the consolidated input market, raising questions about pricing power, trait access, and the speed of next-generation seed development.
The Roundup Litigation Shadow
The Monsanto-Bayer union inherited a massive legal burden. Thousands of lawsuits alleged that glyphosate-based herbicides, branded as Roundup, caused non-Hodgkin lymphoma. By the time the merger closed, Bayer had already lost several high-profile jury trials, resulting in multi-billion-dollar damage awards that sent the company's share price sharply lower.
Bayer mounted a vigorous defense, citing decades of regulatory approvals and scientific studies supporting glyphosate's safety. The company also pursued a sweeping settlement framework, ultimately reaching agreements with tens of thousands of claimants. In 2024, Bayer announced a $2.4 billion settlement to resolve the remaining U.S. Roundup litigation, a figure that shaped the final accounting of the Monsanto-Bayer integration.
Regulatory Scrutiny and Divestitures
Antitrust authorities in the European Union, the United States, and China reviewed the Monsanto-Bayer combination. The EU approved the deal conditionally, requiring Bayer to divest its digital farming platform, Climate FieldView, in certain regions to preserve competition. The U.S. Department of Justice required divestitures in the herbicide-tolerant soybean and cotton seed markets to prevent excessive market concentration.
These forced sales transferred significant assets to competitors, including BASF and a consortium of farmer-owned grain companies. The divestitures illustrate how regulators weighed the scale of the Monsanto-Bayer entity against the need to maintain a diverse seed supply and prevent unilateral price increases.
Impact on Farmers and the Seed Market
For growers, the Monsanto-Bayer merger altered the competitive dynamics of purchasing seed and chemical inputs. The combined company's portfolio spans herbicides, insecticides, fungicides, and traits for drought and pest tolerance. Farmers who relied on Monsanto's Xtend trait system for dicamba-tolerant soybeans found themselves fully integrated into Bayer's product roadmap.
Consolidation in the seed industry means fewer choices at the cash counter. Independent seed analysts have noted that the Monsanto-Bayer entity controls a large share of the corn and soybean market in the United States, making trait stacking and pricing a focal point for farm advocacy groups and antitrust watchdogs.
Innovation and Digital Agriculture
Bayer has positioned the combined Monsanto-Bayer unit at the center of its precision agriculture strategy. FieldView, the digital platform originally developed by Climate Corporation under Monsanto, now serves as a data hub for planting prescriptions, yield monitoring, and agronomic decision support. Integration with Bayer's Crop Science division aims to link field data directly to product recommendations.
The pipeline for gene-edited crops and biologicals has also expanded under the Monsanto-Bayer umbrella. Investments in research aim to reduce chemical input use while maintaining yields, responding to both regulatory pressure and grower demand for more sustainable practices.
The Legacy of Monsanto Under Bayer's Ownership
The Monsanto name, once synonymous with controversial products from Agent Orange to PCBs, now operates as a division within a larger corporation. The Monsanto-Bayer integration has shifted corporate branding, with the word "Monsanto" increasingly absent from public-facing communications. The legal liabilities tied to the company's past remain the most visible inheritance of the merger.
As Bayer absorbs Monsanto's operations, the focus has turned to managing legacy liabilities, integrating digital tools, and navigating a polarized public debate over genetic modification and herbicide use. The long-term success of the Monsanto-Bayer combination will depend on delivering innovation that offsets the reputational and legal costs inherited from one of agriculture's most controversial companies.